Young Diane C.
Known title: SVP, Chief Medical OfficerCIK: 0001648010
Associated companies
Transaction History
| CLDX | ▲ Buy | Option Exercise | 15,000 | $41K | 6/11/2024 | View on chart |
| CLDX | ▼ Sell | Open Market | 45,000 | $1.6M | 6/7/2024 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 19,000 | $197K | 8/17/2022 | View on chart |
| CLDX | ▼ Sell | Open Market | 19,000 | $709K | 8/17/2022 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 45,000 | $122K | 8/17/2022 | View on chart |
| CLDX | ▲ Buy | Option Exercise | 4,600 | $48K | 11/12/2021 | View on chart |
| CLDX | ▼ Sell | Open Market | 4,600 | $198K | 11/12/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Celldex shares dip after positive Phase 3 barzolvolimab results
Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.
Celldex shares dip after positive Phase 3 barzolvolimab results. Celldex reported that its drug barzolvolimab met endpoints in Phase 3 trials for chronic spontaneous urticaria, showing durable responses. Despite these positive results, the stock fell 11%, with some analysts noting that safety concerns appear misplaced. Major firms like Morgan Stanley and Leerink Partners recently raised their price targets, while the company continues to manage a high cash burn rate.